Bidwell Health
Bimatoprost for Eyelash Growth — Clinical Note
Bimatoprost 0.03% is used for upper-eyelash growth when a clinician determines the patient is an appropriate candidate and the patient accepts the eye-color and eyelid-pigmentation counseling.
What is the indication?
Bimatoprost ophthalmic solution 0.03%, sold as Latisse® and as generic bimatoprost, is indicated for hypotrichosis of the eyelashes. In patient language, that means inadequate or sparse eyelashes. Bidwell’s workflow is limited to adults ages 18-64 seeking upper-eyelash enhancement and excludes medical lash loss that needs diagnosis or in-person care.
How does bimatoprost work?
Bimatoprost is a prostaglandin analog. For lash use, it is applied to the skin of the upper eyelid margin at the base of the eyelashes. It is not intended for the lower lid. Results are gradual because lashes grow in cycles; patients should expect weeks of consistent use before judging response.
Who is a reasonable candidate?
A reasonable online candidate has no current eye pain, vision changes, light sensitivity, floaters, infection, eyelid inflammation, glaucoma, ocular hypertension, prescription eye-drop use, recent concerning eye surgery history, pregnancy, breastfeeding, chemotherapy-related lash loss, alopecia areata, trichotillomania, or trauma-related lash loss. Contact lenses are not a block, but they require counseling.
What counseling matters most?
- Apply once nightly to the upper eyelid margin only.
- Use sterile single-use applicators.
- Do not apply to the lower lid.
- Remove contact lenses before application and wait at least 15 minutes before reinserting.
- Blot excess solution to reduce unwanted hair growth on surrounding skin.
- Stop and seek eye care for pain, vision symptoms, severe redness, swelling, or discharge.
What are the major side effects?
The counseling focus is iris pigmentation, eyelid skin pigmentation, itching, redness, irritation, dryness, and unwanted hair growth on exposed skin. Iris pigmentation is treated differently from eyelid darkening because iris change may be permanent. Bidwell stores the dedicated iris-consent version and exact language with the visit record.
When should the patient be referred?
Refer for in-person eye care when symptoms suggest infection, inflammation, vision threat, glaucoma/IOP concern, retinal disease, or unexplained eye pain. Refer to dermatology or the patient’s treating clinician when lash loss appears medical rather than cosmetic.
What documentation should be stored?
For a cosmetic medication with a rare but serious counseling issue, documentation matters. The chart should capture the patient’s medication preference, pharmacy, eye-safety screen, contact-lens status if applicable, and the exact iris-consent language accepted. Bidwell stores the consent version and timestamp in the visit notes so the review trail is visible to the clinician.
What is not part of this workflow?
This workflow does not use photo uploads, does not diagnose eyelid disease, does not manage glaucoma or eye pressure, does not replace an eye exam, and does not treat pediatric or older-adult patients outside Bidwell’s 18-64 platform rule. It is a narrow telehealth workflow for a narrow use case.